<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S1128 IS: Preserving Access to Orphan Drugs Act of 2013</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date></dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 1128</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date>June 11, 2013</action-date>
			<action-desc><sponsor name-id="S351">Mr. Toomey</sponsor> (for himself,
			 <cosponsor name-id="S309">Mr. Casey</cosponsor>, and <cosponsor name-id="S266">Mr. Crapo</cosponsor>) introduced the following bill; which was
			 read twice and referred to the <committee-name committee-id="SSFI00">Committee
			 on Finance</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To clarify the orphan drug exception to the annual fee on
		  branded prescription pharmaceutical manufacturers and
		  importers.</official-title>
	</form>
	<legis-body id="H217770B9975B48CAAAB6B8922A9E76CD" style="OLC">
		<section id="id64E34FE6BA7241F7BD9DAFA155AD7940" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Preserving Access to Orphan Drugs Act
			 of 2013</short-title></quote>.</text>
		</section><section id="H0919A08248C6450AA5F781AFC9E3A146" section-type="subsequent-section"><enum>2.</enum><header>Clarification of
			 orphan drug exception to annual fee on branded prescription pharmaceutical
			 manufacturers and importers</header>
			<subsection commented="no" id="HC6CAA135FAAF4644886FCF712C033886"><enum>(a)</enum><header>In
			 general</header><text display-inline="yes-display-inline">Paragraph (3) of
			 section 9008(e) of the Patient Protection and Affordable Care Act (26 U.S.C.
			 4001 note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>) is amended to read as follows:</text>
				<quoted-block display-inline="no-display-inline" id="HF27DB0DDD42C4EFB8F39B677E227B40C" style="OLC">
					<paragraph commented="no" id="H1E5CD89FCF6A4D7FA67EB61CC3A18FB8"><enum>(3)</enum><header>Exclusion of
				orphan drug sales</header>
						<subparagraph commented="no" id="HD2670A4772D04BAFBA2A957F93416608"><enum>(A)</enum><header>In
				general</header><text display-inline="yes-display-inline">The term
				<term>branded prescription drug sales</term> shall not include sales of any
				drug or biological product—</text>
							<clause commented="no" id="H0E8214AB0ECC42EE87168BCE9F9AFD54"><enum>(i)</enum><text>with respect to
				which a credit was allowed for any taxable year under section 45C of the
				Internal Revenue Code of 1986; or</text>
							</clause><clause commented="no" id="HF708024C1FF14B80B7DCC17B8D17AE9B"><enum>(ii)</enum><text>which is approved
				or licensed by the Food and Drug Administration for marketing solely for one or
				more rare diseases or conditions.</text>
							</clause></subparagraph><subparagraph commented="no" id="HC21879BEC09B4C4DBE91E58F56E00989"><enum>(B)</enum><header>Limitation</header><text>Subparagraph
				(A) shall not apply with respect to any drug or biological product after the
				date on which the drug or biological product is approved or licensed by the
				Food and Drug Administration for marketing for any indication other than the
				treatment of a rare disease or condition.</text>
						</subparagraph><subparagraph commented="no" id="HE2230F38AA6748E3984C9EFCD2E6E70C"><enum>(C)</enum><header>Rare disease or
				condition</header><text>In this paragraph, the term <term>rare disease or
				condition</term> has the meaning given such term under section 45C(d)(1) of the
				Internal Revenue Code of 1986, except that in the case of any drug or
				biological product that has not been designated under section 526 of the
				Federal Food, Drug and Cosmetic Act for a particular indication, determinations
				under such section 45C(d)(1) shall be made on the basis of the facts and
				circumstances as of the date such drug or biological product is approved or
				licensed by the Food and Drug Administration for marketing for the treatment of
				such disease or
				condition.</text>
						</subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection id="H26DA77CC8C8441FBB55E0978A9162317"><enum>(b)</enum><header>Effective
			 date</header><text>The amendment made by this section shall take effect as if
			 included in section 9008 of the Patient Protection and Affordable Care Act (26
			 U.S.C. 4001 note prec.; <external-xref legal-doc="public-law" parsable-cite="pl/111/148">Public Law 111–148</external-xref>).</text>
			</subsection></section></legis-body>
</bill>


